Compare · CNC vs YDES
CNC vs YDES
Side-by-side comparison of Centene Corporation (CNC) and YD Bio Limited (YDES): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNC and YDES operate in Medical Specialities (Health Care), so they compete in similar markets.
- CNC is the larger of the two at $32.11B, about 96.9x YDES ($331.5M).
- Over the past year, CNC is up 126.9% and YDES is down 63.2% - CNC leads by 190.1 points.
- CNC has been more active in the news (12 items in the past 4 weeks vs 5 for YDES).
- CNC has more recent analyst coverage (25 ratings vs 0 for YDES).
- Company
- Centene Corporation
- YD Bio Limited
- Price
- $65.01-0.97%
- $4.91+4.91%
- Market cap
- $32.11B
- $331.5M
- 1M return
- +1.48%
- +117.74%
- 1Y return
- +126.87%
- -63.25%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 12
- 5
- Recent ratings
- 25
- 0
Centene Corporation
Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; and vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
Latest CNC
- California Community Health Workers and Doulas Can Spend More Time Helping Medi-Cal Members, Thanks to Health Net's $900,000 Grant to Pear Suite
- Coordinated Care Brings Free Health Screenings to Washington Communities with Statewide Vision & Dental Van Tour
- Superior HealthPlan has supported more than 312,000 Texas pregnancies since 2022 through the Start Smart for Your Baby® program
- Secretary & General Counsel Koster Christopher sold $3,111,332 worth of shares (47,603 units at $65.36), decreasing direct ownership by 13% to 305,354 units (SEC Form 4)
- Centene Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Centene Announces Planned Chief Financial Officer Transition
- Sixty Compton, California Students to be Selected for Leadership and Health Advocacy Training, Powered by Health Net's $412,000 Investment
- Carolina Complete Health Supports Young Leaders Through AMEXCAN Summer Camp
- MHS Serves Announces Recipients of over $2 Million Investment in Hoosier Employment
- Health Net Providing Special Assistance to Members and Providers Affected by Gann Fire in Calaveras County
Latest YDES
- YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute
- SEC Form 424B3 filed by YD Bio Limited
- SEC Form 6-K filed by YD Bio Limited
- YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute
- YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research
- YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada
- YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services
- YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations
- Director Lu Shao-Ta converted options into 5,749 units of Ordinary Shares, increasing direct ownership by 276% to 7,830 units (SEC Form 4)
- Director Chang Kochi converted options into 5,749 units of Ordinary Shares, increasing direct ownership by 276% to 7,830 units (SEC Form 4)